Resverlogix Corp. (RVXCF)
USD 0.03
(-2.79%)
USD 0.03
(-2.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 67.39 Million USD | -3.52% |
| 2021 | 69.85 Million USD | 0.0% |
| 2019 | 75.49 Million USD | -66.3% |
| 2018 | 224 Million USD | 143.61% |
| 2017 | 91.95 Million USD | -18.22% |
| 2016 | 112.43 Million USD | 16.48% |
| 2015 | 96.52 Million USD | 1.73% |
| 2014 | 94.88 Million USD | 43.24% |
| 2013 | 66.24 Million USD | 32.48% |
| 2012 | 50 Million USD | 419.21% |
| 2011 | 9.63 Million USD | -21.11% |
| 2010 | 12.2 Million USD | 207.51% |
| 2009 | 3.96 Million USD | -45.6% |
| 2008 | 7.29 Million USD | -52.21% |
| 2007 | 15.26 Million USD | -4.68% |
| 2006 | 16.01 Million USD | 2664.7% |
| 2005 | 579.35 Thousand USD | 63.95% |
| 2004 | 353.36 Thousand USD | 262.06% |
| 2003 | 97.59 Thousand USD | -30.21% |
| 2002 | 139.85 Thousand USD | 360.47% |
| 2001 | 30.37 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 75.11 Million USD | 0.0% |
| 2023 Q3 | 79.35 Million USD | 5.64% |
| 2022 Q2 | 70.04 Million USD | -1.23% |
| 2022 Q3 | 70.49 Million USD | 0.64% |
| 2022 FY | 67.39 Million USD | -3.52% |
| 2022 Q1 | 70.92 Million USD | 1.53% |
| 2022 Q4 | 67.39 Million USD | -4.4% |
| 2021 FY | 69.85 Million USD | 0.0% |
| 2021 Q3 | 54.81 Million USD | 3.9% |
| 2021 Q4 | 69.85 Million USD | 27.44% |
| 2021 Q2 | 52.75 Million USD | 5.88% |
| 2021 Q1 | 49.82 Million USD | 0.0% |
| 2020 Q3 | 63.31 Million USD | -17.33% |
| 2020 Q1 | 75.49 Million USD | -13.19% |
| 2020 Q2 | 76.58 Million USD | 1.45% |
| 2019 FY | 75.49 Million USD | -66.3% |
| 2019 Q4 | 86.95 Million USD | -8.91% |
| 2019 Q3 | 95.46 Million USD | -55.43% |
| 2019 Q1 | 224 Million USD | 31.11% |
| 2019 Q2 | 214.17 Million USD | -4.39% |
| 2018 Q3 | 168.41 Million USD | 14.38% |
| 2018 Q4 | 170.86 Million USD | 1.45% |
| 2018 Q1 | 91.95 Million USD | 5.65% |
| 2018 Q2 | 147.23 Million USD | 60.12% |
| 2018 FY | 224 Million USD | 143.61% |
| 2017 Q1 | 112.43 Million USD | 8.12% |
| 2017 FY | 91.95 Million USD | -18.22% |
| 2017 Q4 | 87.03 Million USD | -32.32% |
| 2017 Q2 | 120.79 Million USD | 7.44% |
| 2017 Q3 | 128.61 Million USD | 6.47% |
| 2016 Q1 | 96.52 Million USD | 8.98% |
| 2016 Q4 | 103.99 Million USD | 5.06% |
| 2016 Q3 | 98.97 Million USD | 4.56% |
| 2016 Q2 | 94.65 Million USD | -1.93% |
| 2016 FY | 112.43 Million USD | 16.48% |
| 2015 Q3 | 88.38 Million USD | -1.66% |
| 2015 Q2 | 89.87 Million USD | -5.28% |
| 2015 FY | 96.52 Million USD | 1.73% |
| 2015 Q1 | 94.88 Million USD | 24.36% |
| 2015 Q4 | 88.57 Million USD | 0.21% |
| 2014 Q1 | 66.24 Million USD | -1.95% |
| 2014 FY | 94.88 Million USD | 43.24% |
| 2014 Q3 | 80.05 Million USD | 38.82% |
| 2014 Q2 | 57.67 Million USD | -12.94% |
| 2014 Q4 | 76.29 Million USD | -4.7% |
| 2013 FY | 66.24 Million USD | 32.48% |
| 2013 Q1 | 50 Million USD | 46.07% |
| 2013 Q2 | 89.11 Million USD | 78.23% |
| 2013 Q3 | 84.35 Million USD | -5.34% |
| 2013 Q4 | 67.55 Million USD | -19.91% |
| 2012 FY | 50 Million USD | 419.21% |
| 2012 Q1 | 9.63 Million USD | 7.54% |
| 2012 Q2 | 10.61 Million USD | 10.25% |
| 2012 Q3 | 28.56 Million USD | 169.07% |
| 2012 Q4 | 34.22 Million USD | 19.82% |
| 2011 Q4 | 8.95 Million USD | -2.66% |
| 2011 Q1 | 12.2 Million USD | 499.45% |
| 2011 Q3 | 9.2 Million USD | -11.68% |
| 2011 Q2 | 10.41 Million USD | -14.66% |
| 2011 FY | 9.63 Million USD | -21.11% |
| 2010 Q2 | 2.05 Million USD | -48.27% |
| 2010 Q4 | 2.03 Million USD | -9.96% |
| 2010 Q1 | 3.96 Million USD | 88.77% |
| 2010 FY | 12.2 Million USD | 207.51% |
| 2010 Q3 | 2.26 Million USD | 10.13% |
| 2009 Q3 | 6.65 Million USD | -0.74% |
| 2009 FY | 3.96 Million USD | -45.6% |
| 2009 Q4 | 2.1 Million USD | -68.39% |
| 2009 Q2 | 6.7 Million USD | -8.15% |
| 2009 Q1 | 7.29 Million USD | -16.1% |
| 2008 FY | 7.29 Million USD | -52.21% |
| 2008 Q4 | 8.69 Million USD | 13.63% |
| 2008 Q3 | 7.65 Million USD | -44.33% |
| 2008 Q2 | 13.74 Million USD | -9.95% |
| 2008 Q1 | 15.26 Million USD | -2.02% |
| 2007 FY | 15.26 Million USD | -4.68% |
| 2007 Q4 | 15.58 Million USD | -14.33% |
| 2007 Q2 | 26.15 Million USD | 63.29% |
| 2007 Q1 | 16.01 Million USD | -6.5% |
| 2007 Q3 | 18.18 Million USD | -30.46% |
| 2006 Q2 | 564.13 Thousand USD | -2.63% |
| 2006 Q1 | 579.35 Thousand USD | 158.33% |
| 2006 FY | 16.01 Million USD | 2664.7% |
| 2006 Q4 | 17.13 Million USD | 1518.97% |
| 2006 Q3 | 1.05 Million USD | 87.57% |
| 2005 Q1 | 353.36 Thousand USD | 87.74% |
| 2005 Q4 | 224.27 Thousand USD | -42.69% |
| 2005 FY | 579.35 Thousand USD | 63.95% |
| 2005 Q2 | 378.65 Thousand USD | 7.16% |
| 2005 Q3 | 391.31 Thousand USD | 3.34% |
| 2004 Q1 | 97.59 Thousand USD | -4.21% |
| 2004 FY | 353.36 Thousand USD | 262.06% |
| 2004 Q4 | 188.22 Thousand USD | 17.15% |
| 2004 Q3 | 160.66 Thousand USD | -0.64% |
| 2004 Q2 | 161.7 Thousand USD | 65.68% |
| 2003 Q3 | 100.92 Thousand USD | -21.89% |
| 2003 Q2 | 129.2 Thousand USD | -7.61% |
| 2003 Q4 | 101.88 Thousand USD | 0.96% |
| 2003 FY | 97.59 Thousand USD | -30.21% |
| 2003 Q1 | 139.85 Thousand USD | 89.87% |
| 2002 Q3 | 4805.84 USD | -53.67% |
| 2002 Q4 | 73.65 Thousand USD | 1432.6% |
| 2002 Q1 | 15.69 Thousand USD | 0.0% |
| 2002 Q2 | 10.37 Thousand USD | -33.89% |
| 2002 FY | 139.85 Thousand USD | 360.47% |
| 2001 FY | 30.37 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -245574.917% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -611.986% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 7.003% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -8232.901% |
| Rebus Holdings, Inc. | 5.24 Million USD | -1185.692% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -14.203% |
| Qrons Inc. | 1.48 Million USD | -4427.132% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -5396.272% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 10.043% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -150687.543% |
| Skye Bioscience, Inc. | 14.07 Million USD | -378.929% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -26.435% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -603.359% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -15886.982% |
| SQZ Biotechnologies Company | 50.03 Million USD | -34.687% |
| Intellipharmaceutics International Inc. | 12 Million USD | -461.223% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -1649.898% |
| Mesoblast Limited | 188.44 Million USD | 64.236% |
| Marizyme, Inc. | 26.67 Million USD | -152.649% |
| Genus plc | 485 Million USD | 86.104% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -1053.523% |
| Pharming Group N.V. | 244.07 Million USD | 72.387% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -3252.818% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -2578.347% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -1673.579% |
| ContraFect Corporation | 32.53 Million USD | -107.175% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -3301.591% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -1660.768% |
| IMV Inc. | 37.93 Million USD | -77.672% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -472.21% |
| MultiCell Technologies, Inc. | 1617.67 USD | -4166139.097% |
| ONE Bio Corp. | 27.49 Million USD | -145.114% |
| Accustem Sciences Inc. | 1.07 Million USD | -6144.771% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 12.944% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -3086.468% |
| Q BioMed Inc. | 8.13 Million USD | -728.68% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 18.736% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -1209.669% |
| Biomind Labs Inc. | 1.49 Million USD | -4397.228% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 43.232% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -645.35% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -266.215% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -4600.316% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -47330.24% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -33411.009% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -1072.957% |
| GB Sciences, Inc. | 5.41 Million USD | -1144.029% |
| Alpha Cognition Inc. | 7.16 Million USD | -840.658% |
| HST Global, Inc. | 593.59 Thousand USD | -11253.907% |
| CSL Limited | 18.62 Billion USD | 99.638% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -5252.317% |
| Halberd Corporation | 728.71 Thousand USD | -9148.558% |
| Enzolytics Inc. | 365.26 Million USD | 81.549% |
| Agentix Corp. | 2.51 Million USD | -2584.506% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -7935.463% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 84.853% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -3832.089% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -172.351% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -466.205% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -1738.826% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1587.539% |
| Zenith Capital Corp. | 27.56 Thousand USD | -244362.984% |
| Genscript Biotech Corporation | 1.32 Billion USD | 94.917% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -28140.046% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -1704.78% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -9799.036% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -2385.432% |
| Kadimastem Ltd | 3.5 Million USD | -1822.926% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -100597.754% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -34.084% |
| BioStem Technologies, Inc. | 15.9 Million USD | -323.75% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -14403.152% |
| LadRx Corporation | 2.2 Million USD | -2962.719% |
| Cell Source, Inc. | 15.8 Million USD | -326.376% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1134.898% |
| Regen BioPharma, Inc. | 5.45 Million USD | -1134.898% |
| NovAccess Global Inc. | 7.86 Million USD | -757.376% |
| Affymax, Inc. | 8.87 Million USD | -659.734% |
| Itoco Inc. | 1.65 Million USD | -3976.821% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -3185.102% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -1014.168% |
| Mobile Lads Corp. | 1.31 Million USD | -5031.036% |
| CytoDyn Inc. | 127.89 Million USD | 47.303% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -161138.307% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -4202.668% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -510.179% |
| SYBLEU INC | 681.41 Thousand USD | -9790.624% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -1004.508% |
| International Stem Cell Corporation | 5.27 Million USD | -1177.165% |
| Bioxytran, Inc. | 3.24 Million USD | -1974.042% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -10669.42% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -1359.696% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -64.397% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -202.699% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -3227.562% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -1130.303% |
| Neutra Corp. | 973.52 Thousand USD | -6822.855% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -132.28% |
| PureTech Health plc | 125.58 Million USD | 46.334% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1693.818% |
| IXICO plc | 1.9 Million USD | -3446.613% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -228.297% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 34.772% |
| CSL Limited | 18.62 Billion USD | 99.638% |
| Cellectis S.A. | 249.36 Million USD | 72.973% |